Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 14/20 | 0.55 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | HTR7 | P34969 | 2/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | TOP2A | P11388 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4426419 | 0.79 | HTR6 (0.51) | HTR6MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4429045 | 0.76 | PKM (0.40) | HTR6TOP2AHTT | |
| SCHEMBL4418543 | 0.73 | KMT2A (0.43) | HTR6TOP2AKMT2AMAPTSMN1; SMN2 | |
| SCHEMBL4422242 | 0.73 | HTT (0.40) | HTR6MAPTSMN1; SMN2HTT | |
| SCHEMBL4276328 | 0.73 | HTR6 (0.42) | HTR6HTR7MEN1KMT2AMAPT | |
| SCHEMBL4269778 | 0.73 | MEN1 (0.43) | HTR6HTR7MEN1KMT2AMAPT | |
| SCHEMBL4416995 | 0.71 | HTR6 (0.50) | HTR6TOP2A | |
| SCHEMBL4430912 | 0.70 | KDM4E (0.38) | HTR6HTR2AHTR2CTOP2AMAPT | |
| SCHEMBL4269436 | 0.70 | HTR6 (0.54) | HTR6HTR2AHTR7HTR2CDRD3 | |
| SCHEMBL13354930 | 0.70 | CYP1A2 (0.56) | TOP2AMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1654258-A1 | SULFONYLDIHYDRO- BENZIMIDAZOLONE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | Wyeth (US) | 2006-05-10 | — | — | EP | claimed |
| WO-2005009996-A1 | SULFONYLDIHYDRO- BENZIMIDAZOLONE COMPOUNDS AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH (US) | 2005-02-03 | — | — | WO | claimed |
| US-20050020575-A1 | Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-01-27 | — | — | US | claimed |
| US-7544701-B2 | Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2009-06-09 | — | — | US | disclosed |
| US-20050020575-A1 | Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020575-A1 | Sulfonyldihydrobenzimidazolone compounds as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR1B | HTR6 1/4885HTR2A 8/4885HTR7 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.